MaxCyte — Third Quarter 2026 Earnings Summary

Financial Performance

• Core business revenue for the third quarter of 2026 was approximately $8.1 million, representing a 26% increase compared to the third quarter of 2025.
• Strategic Platform License (SPL) Program-related revenue for the third quarter exceeded $1.0 million, including $1.0 million in milestone revenue received during the quarter.
• Royalty revenue associated with the SPL Program will be reported with full financial results on November 10, 2026.
• Preliminary results are unaudited and subject to change upon completion of quarterly closing and review procedures.

Guidance and Future Outlook

• Full year 2026 revenue guidance was raised to approximately $34 million, up from the prior guidance range of $30 million to $32 million.
• Core business revenue guidance for the full year 2026 was raised to approximately $28 million, compared to the prior guidance of $25 million to $27 million.
• SPL Program-related revenue guidance for the full year 2026 was raised to approximately $6 million, compared to the prior guidance of approximately $5 million.
• The updated SPL guidance includes approximately $4 million from milestone payments and approximately $2 million from commercial royalties.
• Management expects approximately 15% year-over-year growth in core business revenue for the second half of 2026.
• Two pivotal trials under SPL partnerships are supported, with potential approval as early as 2027.

Business Segments and Product Lines

• Growth in the third quarter was driven by accelerated instrument purchasing from a large customer, which was originally anticipated to occur in the fourth quarter.
• The company is supporting more late-stage clinical programs under SPL partnerships than ever before.
• The company achieved its second milestone from an SPL partner in 2026.

Management Commentary and Tone

• Maher Masoud, President and CEO, stated that preliminary third quarter and total second half revenue are ahead of expectations.
• Management expressed encouragement regarding the return to double-digit growth and the acceleration of instrument purchasing.
• The company remains focused on executing strategic priorities, strengthening its position as a leading enabling technology partner in cell and gene therapy, and building a foundation for sustainable long-term growth.

Other Key Points

• MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026, at 4:30 p.m. Eastern Time.
• A live and archived webcast will be available on the "Events" section of the MaxCyte investor website.
• The press release includes a standard "Forward-Looking Statements" section detailing risks related to future results, market conditions, capital resources, and clinical program advancements.
• MaxCyte's Flow Electroporation® technology and SeQure™ gene editing risk assessment services are highlighted as key platform technologies.